Biogen (BIIB) vs Exelixis (EXEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exelixis (EXEL) has outperformed Biogen (BIIB) over the past year, gaining 52.7% versus a gain of 44.7%. Over five years, EXEL leads with a +170.5% price change compared with -22.3% for BIIB. Biogen is the larger company by market cap ($33.28 billion vs $14.94 billion), about 2.2 times the size, while Exelixis is growing revenue faster (+7.0% vs +2.2%).
On valuation, Biogen trades at a lower forward P/E (13.6x vs 14.1x for Exelixis). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | EXEL |
|---|---|---|
| Share price | $225.26 | $60.30 |
| Market cap | $33.28B | $14.94B |
| 1-day change | +3.13% | +2.17% |
| YTD return | +24.12% | +34.66% |
| 1-year return | +44.68% | +52.74% |
| 5-year return | -22.32% | +170.49% |
| P/E ratio (TTM) | 40.01 | 19.02 |
| Forward P/E | 13.62 | 14.11 |
| EPS (TTM) | $5.63 | $3.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $2.32B |
| Revenue growth (YoY) | +2.22% | +6.98% |
| Net income (latest FY) | $1.29B | $782.57M |
| Gross margin | 75.69% | 96.39% |
| Operating margin | — | 37.59% |
| Net margin | 13.07% | 33.73% |
| 52-week high | $230.49 | $61.14 |
| 52-week low | $138.00 | $33.76 |
| Distance from 52-week high | -2.27% | -1.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +5.74% | -9.57% |
| Average volume | 1.06M | 2.34M |
| Shares outstanding | 147.75M | 247.78M |
| Employees | 7,500 | 1,077 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 2.2 times larger than Exelixis by market value ($33.28B vs $14.94B).
- Biogen trades at a higher earnings multiple (40.0x vs 19.0x trailing P/E).
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 13.1 cents for Biogen.
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
BIIB vs EXEL FAQ
Which is bigger, Biogen or Exelixis?
Biogen (BIIB) is larger, with a market capitalization of $33.28B compared with $14.94B for Exelixis (EXEL).
Which stock has performed better over the past year, BIIB or EXEL?
EXEL returned +52.74% over the past 12 months, compared with +44.68% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or EXEL?
EXEL has the lower trailing P/E at 19.0, versus 40.0 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biogen and Exelixis in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.